1
Clinical Trials associated with DC Vaccine(Oncovir)Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence
Vaccine adjuvants are compounds used to increase specific immune responses to antigens, but have minimal toxicity or lasting immune effects on their own. This study investigates the use of dendritic cells as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides compared to Montanide® in study subjects with melanoma in complete clinical remission.
100 Clinical Results associated with DC Vaccine(Oncovir)
100 Translational Medicine associated with DC Vaccine(Oncovir)
100 Patents (Medical) associated with DC Vaccine(Oncovir)
100 Deals associated with DC Vaccine(Oncovir)